TY - JOUR
T1 - State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus
T2 - Summary of a scientific workshop
AU - Schuind, Anne E.
AU - Rees, Helen
AU - Schiller, John
AU - Mugo, Nelly
AU - Dull, Peter
AU - Barnabas, Ruanne
AU - Clifford, Gary M.
AU - Liu, Gui
AU - Madhi, Shabir A.
AU - Morse, Rebecca B.
AU - Moscicki, Anna Barbara
AU - Palefsky, Joel M.
AU - Plotkin, Stanley
AU - Sierra, Mónica S.
AU - Slifka, Mark K.
AU - Vorsters, Alex
AU - Kreimer, Aimée R.
AU - Didierlaurent, Arnaud M.
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/10
Y1 - 2023/10
N2 - The burden of cervical cancer is disproportionately distributed globally, with the vast majority of cases occurring in low- and middle-income countries. Women with human immunodeficiency virus (HIV) (WWH) are at increased risk of human papillomavirus (HPV) infection and cervical cancer as compared to HIV-negative individuals. HPV vaccination remains a priority in regions with a high burden of cervical cancer and high HIV prevalence. With HPV vaccines becoming more accessible, optimal use beyond the initial World Health Organization-recommended target population of 9 to 14-year-old girls is an important question. In March 2022, a group of experts in epidemiology, immunology, and vaccinology convened to discuss the state-of-the-science of HPV vaccination in WWH. This report summarizes the proceedings: review of HIV epidemiology and its intersection with cervical cancer burden, immunology, HPV vaccination including reduced-dose schedules and experience with other vaccines in people with HIV (PWH), HPV vaccination strategies and knowledge gaps, and outstanding research questions. Studies of HPV vaccine effectiveness among WWH, including duration of protection, are limited. Until data from ongoing research is available, the current recommendation for WWH remains for a multi-dose HPV vaccination regimen. A focus of the discussion included the potential impact of HIV acquisition following HPV vaccination. With no data currently existing for HPV vaccines and limited information from non-HPV vaccines, this question requires further research. Implementation research on optimal HPV vaccine delivery approaches for WWH and other priority populations is also urgently needed.
AB - The burden of cervical cancer is disproportionately distributed globally, with the vast majority of cases occurring in low- and middle-income countries. Women with human immunodeficiency virus (HIV) (WWH) are at increased risk of human papillomavirus (HPV) infection and cervical cancer as compared to HIV-negative individuals. HPV vaccination remains a priority in regions with a high burden of cervical cancer and high HIV prevalence. With HPV vaccines becoming more accessible, optimal use beyond the initial World Health Organization-recommended target population of 9 to 14-year-old girls is an important question. In March 2022, a group of experts in epidemiology, immunology, and vaccinology convened to discuss the state-of-the-science of HPV vaccination in WWH. This report summarizes the proceedings: review of HIV epidemiology and its intersection with cervical cancer burden, immunology, HPV vaccination including reduced-dose schedules and experience with other vaccines in people with HIV (PWH), HPV vaccination strategies and knowledge gaps, and outstanding research questions. Studies of HPV vaccine effectiveness among WWH, including duration of protection, are limited. Until data from ongoing research is available, the current recommendation for WWH remains for a multi-dose HPV vaccination regimen. A focus of the discussion included the potential impact of HIV acquisition following HPV vaccination. With no data currently existing for HPV vaccines and limited information from non-HPV vaccines, this question requires further research. Implementation research on optimal HPV vaccine delivery approaches for WWH and other priority populations is also urgently needed.
KW - Epidemiology
KW - HPV vaccine
KW - Human papillomavirus (HPV)
KW - Immunization
KW - Immunology
KW - Prevention
KW - Vaccination strategies
KW - human immunodeficiency virus (HIV)
KW - women with HIV (WWH)
UR - http://www.scopus.com/inward/record.url?scp=85166642991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85166642991&partnerID=8YFLogxK
U2 - 10.1016/j.pmedr.2023.102331
DO - 10.1016/j.pmedr.2023.102331
M3 - Review article
AN - SCOPUS:85166642991
SN - 2211-3355
VL - 35
JO - Preventive Medicine Reports
JF - Preventive Medicine Reports
M1 - 102331
ER -